Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1

Status

Recruiting 3

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Non-Small-Cell Lung 41Squamous Cell Carcinoma of Head and Neck 22Lung Neoplasms 22Oropharyngeal Neoplasms 14Nasopharyngeal Carcinoma 13Carcinoma 12Urinary Bladder Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 8Head and Neck Neoplasms 8Mouth Neoplasms 6Laryngeal Neoplasms 6Small Cell Lung Carcinoma 5Neoplasms 5Hypopharyngeal Neoplasms 5Cholangiocarcinoma 5Biliary Tract Neoplasms 5Stomach Neoplasms 4Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Endometrial Neoplasms 4Colorectal Neoplasms 4Uterine Cervical Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Lymphoid Interstitial Pneumonia 3Lung Diseases 3Carcinoma, Transitional Cell 3Carcinoma, Squamous Cell 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3

Interventions

pembrolizumab 10Specimen Handling 8Magnetic Resonance Spectroscopy 7enfortumab vedotin 5Nivolumab 5Ipilimumab 4Gemcitabine 4Cisplatin 3CTLA-4 Antigen 3sacituzumab govitecan 2Taxes 2Paclitaxel 2Mitomycin 2Immunoglobulin G 2Docetaxel 2Disulfides 2Carboplatin 2tislelizumab 1temsirolimus 1tazemetostat 1sapanisertib 1relatlimab 1lenvatinib 1eribulin 1erdafitinib 1durvalumab 1cabozantinib 1belinostat 1atezolizumab 1Valproic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Cisplatin × 30 days × Clear all
NCT06524544 2026-05-27

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
320 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT07129993 2026-05-14

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Daiichi Sankyo

Phase 2/3 Recruiting
630 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07566156 2026-05-11

EV-309

Astellas Pharma Inc

Phase 3 Recruiting
390 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡